文献速递血脂与心血管预防

PCSK9抑制剂:经济学与政策

PCSK9 Inhibitors: Economics and Policy.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本文讨论PCSK9抑制剂在降低低密度脂蛋白胆固醇的同时是否降低死亡率尚不明确;其美国年标价超过14500美元,远高于仿制他汀,成本效益未达美国公认良好价值基准,大幅降价可改善价值,高自付费用可能影响可及性与长期依从性,若所有潜在合格患者均治疗则预算影响巨大。

要点

  • PCSK9抑制剂大幅降低LDL-C,但是否降低死亡率尚不明确。
  • 美国年标价超14500美元,比仿制他汀高100倍以上。
  • 成本效益未达美国公认良好价值基准,大幅降价可改善价值。

核心结论

  • PCSK9抑制剂是否降低死亡率尚不明确。
  • 其美国标价远高于仿制他汀,成本效益未达公认良好价值基准。
  • 大幅降价可改善其价值,高自付费用可能影响可及性与长期依从性。

主要发现

  • PCSK9抑制剂大幅降低低密度脂蛋白胆固醇,但是否降低死亡率尚不明确。
  • 美国年标价超过14500美元,比仿制他汀高100倍以上。
  • 仅一小部分较高成本可能通过预防心血管事件回收。
  • 高自付费用可能阻碍可及性并降低长期依从性。
  • 若所有潜在合格患者均接受治疗,预算影响将非常大。

临床怎么用

  • 对个体患者,需考虑高自付费用对可及性和长期依从性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently unclear whether they also reduce mortality. The list prices of PCSK9 inhibitors in the United States (>$14,500 per year) are >100× higher than generic statins, and only a small fraction of their higher cost is likely to be recovered by prevention of cardiovascular events. The projected cost effectiveness of PCSK9 inhibitors does not meet generally accepted benchmarks for good value in the United States, but their value would be improved by substantial price reductions. For individual patients, the high out-of-pocket costs of PCSK9 inhibitors may impede access and reduce long-term adherence. The budgetary impact of PCSK9 inhibitors would be very large if all potentially eligible patients were treated, which poses dilemmas for policymakers, payers, and society.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hlatky MA, Kazi DS. PCSK9 Inhibitors: Economics and Policy. J Am Coll Cardiol. 2017. PMID: 29169476. doi:10.1016/j.jacc.2017.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。